BHST: bioharvest.com Company Buyout Price

The visualized price action of BioHarvest Sciences (BHST) demonstrates a market trend, with the Enterprise Value standing at 39.86. The business relies on the production of biopharma components and wellness products through proprietary plant cell synthesis. Local laboratories allow the company to eliminate agricultural risks while optimizing costs and logistics. Ambitious management is betting on a technological breakthrough and the successful launch of innovations.

BHST (bioharvest.com) Total Company Value history from 11/23/2025 to 10/28/2026

BioHarvest Sciences (BHST) - metric breakdowns and financial figures

- price and consensus price forecast:

Price Performance Chart BioHarvest Sciences, Inc.|BHST - Price Target Chart

- market capitalization data:

Market Capitalization BioHarvest Sciences|BHST - Real Price to Acquire Entire Company

- book capitalization data:

Book Price of a Share BioHarvest Sciences|BHST - Company Book Value|Market Capitalization to Net Assets bioharvest.com|BHST - Company Total Assets

- debt and liquidity data:

Comprehensive company analysis:BioHarvest Sciences, Inc. (BHST)

Professional selection of resilient assets is based on identifying the true market bottom by analyzing the actual business buyout value. The calculated Enterprise Value sums market capitalization and debt while subtracting liquidity, allowing for an assessment of the financial stability of BioHarvest Sciences (BHST) amid intense pressure from biotech behemoths and chemical corporations.

Competitor analysis for BioHarvest Sciences

Haleon PLC - Value Adjusted for Debt and Cash|Total Company Value KVUE (Kenvue Corp)|Verona Pharma Inc. (VRNA) - Company Buyout Price|MENS - Real Price to Acquire Entire Company|LGND (ligand.com) - Aggregate Business Value|Total Company Value Amneal AMRX|Full Business Value Perrigo Company PLC|Alvotech Corp (ALVO) - Enterprise Value|Value Adjusted for Debt and Cash Liquidia Inc. (LQDA)|Enterprise Value GLPG (Galapagos NV)|anipharmaceuticals.com - Enterprise Value|Total Company Value MannKind (MNKD)|AMPH: Value Adjusted for Debt and Cash|PCRX (Pacira) - Total Company Value|ARS Corp (SPRY) - Real Price to Acquire Entire Company|TBPH (Theravance Biopharma) - Enterprise Value|Enterprise Value aquestive.com (AQST)|scPharmaceuticals Inc. (SCPH) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash TECX (tectonictx.com)|TNXP: Total Company Value|SXTC - Total Enterprise Value|Real Price to Acquire Entire Company Eupraxia Pharma EPRX|EXOZ - Aggregate Business Value|Enterprise Value oramed.com ORMP|Entera Bio (ENTX) - Value Adjusted for Debt and Cash|Enterprise Value HYFT (MindWalk)|Total Enterprise Value ABVC|Cumberland Pharmaceuticals (CPIX) - Total Company Value|Value Adjusted for Debt and Cash quantumbiopharma.com (QNTM)|Enterprise Value FibroGen FGEN|Total Company Value Telomir Pharmaceuticals Inc TELO|Enterprise Value RANI (Rani Therapeutics Inc)|SNYR: Company Buyout Price|Total Company Value RLYB|Lexaria Bioscience Corp. (LEXX) - Total Enterprise Value|PULM - Enterprise Value|Value Adjusted for Debt and Cash Pheton|Enterprise Value APM|Enterprise Value LYRA (Lyra Therapeutics Inc)|Total Company Value Impact BioMedical|TNFA - Value Adjusted for Debt and Cash|YCBD - Real Price to Acquire Entire Company|PRFX - Total Company Value|Enterprise Value CYTO|LIPO (Lipella Pharma) - Total Enterprise Value|OPTN: Total Company Value|Company Buyout Price pieris.com (PIRS)|Real Price to Acquire Entire Company Procaps|Aggregate Business Value Petros Pharmaceuticals Inc PTPI|Real Price to Acquire Entire Company Qilian International Holding Group Limited|ACELYRIN Inc. - Value Adjusted for Debt and Cash|Total Company Value TFFP (TFF Pharmaceuticals)